Comparative Pharmacology
Head-to-head clinical analysis: CALCIUM DISODIUM VERSENATE versus PENICILLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIUM DISODIUM VERSENATE versus PENICILLAMINE.
CALCIUM DISODIUM VERSENATE vs PENICILLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Category C
Category C
Chelating Agent
Chelating Agent